Floatz logo

Fluconazole

Infectious Disease

Medical College of WisconsinSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Infectious Disease cohort.

Asset / SponsorPhaseRating
Sulfamethoxazole
Radboud University Medical Center
Phase 4A
Trimethoprim
Radboud University Medical Center
Phase 4A
Ciprofloxacin
Radboud University Medical Center
Phase 4BBB
Fosfomycin
Radboud University Medical Center
Phase 4BB
Nivestim
Cellerant Therapeutics
Phase 3BB

View all 48 →

Same molecule, other indications

Fluconazole is also rated in:

systemic mycosisDormant
BB
Indicative · Phase 4
69 / 100
View asset →
candidiasis, invasiveActive
BB
Indicative · Phase 4
69 / 100
View asset →
fungal infectious diseaseActive
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →